Hennion & Walsh Asset Management Inc. Has $170,000 Stake in Definitive Healthcare Corp. (NASDAQ:DH)

Hennion & Walsh Asset Management Inc. boosted its holdings in Definitive Healthcare Corp. (NASDAQ:DH) by 62.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,940 shares of the company’s stock after purchasing an additional 14,609 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Definitive Healthcare were worth $170,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of DH. Bleakley Financial Group LLC acquired a new position in shares of Definitive Healthcare in the 3rd quarter valued at approximately $74,000. Norden Group LLC acquired a new position in shares of Definitive Healthcare in the 1st quarter valued at approximately $83,000. SG Americas Securities LLC acquired a new position in shares of Definitive Healthcare in the 3rd quarter valued at approximately $84,000. Sanctuary Advisors LLC acquired a new position in shares of Definitive Healthcare in the 2nd quarter valued at approximately $85,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Definitive Healthcare in the 2nd quarter valued at approximately $109,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Trading Down 1.4 %

NASDAQ:DH opened at $4.16 on Thursday. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $490.61 million, a price-to-earnings ratio of -2.40, a PEG ratio of 6.27 and a beta of 1.33. The firm has a fifty day simple moving average of $4.41 and a two-hundred day simple moving average of $5.15. Definitive Healthcare Corp. has a 12 month low of $3.19 and a 12 month high of $10.62.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.09. The firm had revenue of $63.70 million during the quarter, compared to analysts’ expectations of $63.19 million. Definitive Healthcare had a negative net margin of 156.65% and a positive return on equity of 0.98%. The business’s revenue was up 4.4% on a year-over-year basis. During the same period last year, the company earned $0.08 earnings per share. Analysts expect that Definitive Healthcare Corp. will post 0.07 EPS for the current fiscal year.

Analyst Ratings Changes

DH has been the subject of a number of research analyst reports. Robert W. Baird lowered their price objective on shares of Definitive Healthcare from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. BTIG Research initiated coverage on shares of Definitive Healthcare in a research report on Tuesday, September 17th. They set a “buy” rating and a $7.00 price objective for the company. Morgan Stanley reduced their target price on shares of Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 6th. Barclays decreased their price target on shares of Definitive Healthcare from $6.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 7th. Finally, Stifel Nicolaus decreased their price target on shares of Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating for the company in a research report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $5.81.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.